These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 4660197

  • 21. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.
    Brown JJ, Davies DL, Ferriss JB, Fraser R, Haywood E, Lever AF, Robertson JI.
    Br Med J; 1972 Jun 24; 2(5816):729-34. PubMed ID: 4338668
    [Abstract] [Full Text] [Related]

  • 22. Spironolactone as a nonspecific treatment for primary aldosteronism.
    Bravo EL, Dustan HP, Tarazi RC.
    Circulation; 1973 Sep 24; 48(3):491-8. PubMed ID: 4726231
    [No Abstract] [Full Text] [Related]

  • 23. Failure of aspirin to antagonize the antihypertensive effect of spironolactone in low-renin hypertension.
    Hollifield JW.
    South Med J; 1976 Aug 24; 69(8):1034-6. PubMed ID: 785608
    [Abstract] [Full Text] [Related]

  • 24. Treatment of hypertension with hydrochlorothiazide and spironolactone.
    Ogilvie RI, Ruedy J.
    Can Med Assoc J; 1969 Nov 15; 101(10):61-4. PubMed ID: 5348877
    [Abstract] [Full Text] [Related]

  • 25. Controlled treatment of primary hypertension with propranolol and spironolactone. A crossover study with special reference to initial plasma renin activity.
    Karlberg BE, Kågedal B, Tegler L, Tolagen K, Bergman B.
    Am J Cardiol; 1976 Mar 31; 37(4):642-9. PubMed ID: 769527
    [Abstract] [Full Text] [Related]

  • 26. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone.
    Vaughan ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, Baer L.
    Am J Cardiol; 1973 Sep 20; 32(4):523-32. PubMed ID: 4729722
    [No Abstract] [Full Text] [Related]

  • 27. Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism.
    Hoffbrand BI, Edmonds CJ, Smith T.
    Br Med J; 1976 Mar 20; 1(6011):682-4. PubMed ID: 766908
    [Abstract] [Full Text] [Related]

  • 28. [Use of spironolactone and indapamide in the treatment of low-renin arterial hypertension].
    Naudzhunas A, Bagdonas G, Yankauskene L, Kazanavichus G.
    Ter Arkh; 2006 Mar 20; 78(2):61-4. PubMed ID: 16613101
    [Abstract] [Full Text] [Related]

  • 29. The effects of four months' treatment with spironolactone on systemic blood pressure, cardiac output and plasma renin activity in hypertensive patients.
    Bevegård S, Castenfors J, Danielson M.
    Acta Med Scand; 1977 Mar 20; 202(5):373-7. PubMed ID: 920261
    [Abstract] [Full Text] [Related]

  • 30. Effects of combined therapy with amiloride and hydrochlorothiazide on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in hypertensive patients.
    Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J.
    Eur J Clin Pharmacol; 1986 Mar 20; 30(2):151-6. PubMed ID: 3519243
    [Abstract] [Full Text] [Related]

  • 31. [Relations between hypotensive effect and modifications of volemia and plasma renin activity in patients with essential hypertension treated using spironolactone].
    Pessina AC, Corgnati A, Palù CD.
    Minerva Med; 1977 Feb 18; 68(8):509-14. PubMed ID: 846681
    [Abstract] [Full Text] [Related]

  • 32. [Antihypertensive effect of spironolactone (author's transl)].
    Liebau H, Jarosch-von Schweder W.
    Klin Wochenschr; 1974 Sep 01; 52(17):834-41. PubMed ID: 4449189
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effect of high dose spironolactone and chlorthalidone in essential hypertension: relation to plasma renin activity and plasma volume.
    Hunyor SN, Zweifler AJ, Hansson L, Schork MA, Ellis C.
    Aust N Z J Med; 1975 Feb 01; 5(1):17-24. PubMed ID: 1057909
    [Abstract] [Full Text] [Related]

  • 35. Low renin essential hypertension in a child.
    Leumann EP, Nussberger J, Vetter W.
    Helv Paediatr Acta; 1976 Jan 01; 30(4-5):357-63. PubMed ID: 1245435
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension.
    Jeunemaitre X, Charru A, Chatellier G, Degoulet P, Julien J, Plouin PF, Corvol P, Ménard J.
    Am J Cardiol; 1988 Nov 15; 62(16):1072-7. PubMed ID: 3189169
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension.
    van Brummelen P, Schalekamp M, de Graeff J.
    Acta Med Scand; 1978 Nov 15; 204(3):151-7. PubMed ID: 696414
    [Abstract] [Full Text] [Related]

  • 40. Essential hypertension: a metabolic cause? A hypothesis.
    Macieira-Coelho E, Garcia-Alves M, Reis-Valle A.
    Angiology; 1985 May 15; 36(5):305-9. PubMed ID: 3896046
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.